Beyond the Safety Check: Why First-in-Human Trials Demand a New Approach in 2026

The era of the “simple” Phase I safety study is over.

For emerging biotechs often operating with the classic “two scientists, one molecule” structure, this shift creates both risk and opportunity. First-in-human trials have evolved from regulatory checkpoints into data-rich, adaptive investigations.

The question is no longer just “Is this compound safe?”

It’s “How can these data accelerate my development timeline, de-risk my program, and ensure efficient use of capital?”

In a 2024 industry survey, 38% of respondents cited regulatory compliance as a top challenge in Phase I trials, while 35% pointed to biomarker selection.¹ These aren’t execution problems; they’re critical strategy decision points that demand a different approach to contract research organization (CRO) selection and early clinical design.

The new regulatory reality

Regulatory agencies have raised the bar. FDA and the European Medicines Agency (EMA) now expect sponsors to justify why a Phase II dose was selected, not merely prove it was tolerated. This means it’s critical to build exposure–response relationships, target engagement confirmation, and mechanism validation into early protocols from day one.

Meanwhile, adaptive trial designs continue to rise.² Modern first-in-human protocols answer multiple questions simultaneously: testing biomarker hypotheses, probing pharmacodynamic effects, and optimizing formulations within dose escalation. When designed well, Phase I trials become a strategic decision tool that directly shapes the Phase II program.

For resource-constrained biotechs, the margin for error has narrowed. A poorly designed protocol delays your timeline and generates data that fail to answer the questions regulators and investors need answered.

The case for specialization

Many CROs offer early phase capabilities, but there’s a meaningful difference between organizations that commoditize Phase I trials and those with teams dedicated to a scientific and strategic trial design.

Specialist scientific CRO teams develop pattern recognition that generalists cannot match. They’ve seen which protocol designs lead to costly amendments and ethics approval delays, recognize the biomarker strategies that hold up under regulatory scrutiny, and know how to run parallel PK/PD and patient cohort studies to better inform later phase decisions.

Purpose-built infrastructure matters as well. Phase I units and highly specialized operational teams with deep first-in-human study experience operate with established processes that compress timelines while maintaining the documentation standards global regulators require.

What is the hidden cost of fragmentation?

One consequential mistake biotechs make is fragmenting their CRO strategy across development phases, selecting one vendor for Phase I, then switching for Phase II. This can be a real program timeline killer.

Every transition means rebuilding relationships, reeducating teams on your molecule’s nuances, and reestablishing data standards. Critical institutional knowledge—why certain decisions were made, what the data actually showed—walks out the door with each switch.

For capital-constrained biotechs, these inefficiencies have real consequences. Every CRO switch burns runway.

Every avoidable amendment costs time and money, while every knowledge transfer increases the risk of expensive mistakes. The cumulative effect can be the difference between reaching the next milestone and running out of capital before you get there.

Rethinking geography as strategy

Where you conduct early phase trials has become a strategic lever. Australia has emerged as a compelling launchpad for first-in-human studies, offering regulatory efficiency and financial incentives that directly impact runway.

Studies can move from final protocol to first patient dosed in five to six weeks without requiring an investigational new drug application. The Australian government offers a 43.5% R&D tax rebate on eligible expenditures, providing capital that can be reinvested immediately.³

Critically, data generated in Australia are accepted by FDA, EMA, and other major authorities. More than 280 global Phase III programs conducted their Phase I in Australia before expanding, demonstrating this isn’t a trade-off between speed and regulatory credibility.

The opportunity? To start fast in a favorable environment, generate globally accepted data, then scale into other regions. Ideally, this should be done with the same partner who understands your molecule and development strategy.

Choosing the right partner

Given these dynamics, what should biotechs prioritize?

• First, look for scientific depth beyond protocol execution. You need a partner who functions as a drug development accelerator, asking the right questions early and partnering with biotechs to design trials that generate compelling data.
• Second, ensure global regulatory strategy expertise from day one, so early trials meet FDA, EMA, and other requirements without costly retrofitting.
• Third, prioritize partners who can scale with you through Proof of Concept, preserving continuity and institutional knowledge.
• Last but not least, look for a track record with companies like yours—CROs built for the pace and innovation of biotechs, not big pharma timelines.

Phase I is your foundation, so build it strong

The biotechs that navigate 2026 successfully will recognize early phase development for what it has become: not a regulatory hurdle, but the foundation upon which their asset’s value is built. By investing in specialized expertise, leveraging strategic geography, and prioritizing continuity, emerging companies can de-risk their programs and accelerate their path to proof of concept.

When capital is critical and timelines are essential, getting early phase right isn’t just good science. It’s everything.

References

1. ICON. Overcoming the first hurdles: navigating early phase challenges for biotechs. Blog Post. Dec. 2, 2024. Accessed Jan. 29, 2026. https://www.iconplc.com/insights/blog/2024/12/03/leading-early-phase-challenges-biotechs
2. Lee H, Hwang S, Jang IJ, Chung JY, Oh J. Adaptive design clinical trials: current status by disease and trial phase in various perspectives. Transl Clin Pharmacol. 2023;31(4):202-216. doi: 10.12793/tcp.2023.31.e21
3. Avance Clinical. Why Australia is the best place in the world for early phase studies. Accessed Jan. 29, 2026. https://www.avancecro.com/the-australian-advantage/

About the Author

Ben Edwards is chief operating officer at Avance Clinical, an Australia-headquartered CRO.